Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $3.7M in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President | Aug 03 '26 | Option Exercise | $1.01 | 2,500 | $2,525 | 19,717 | Aug 03 06:14 PM |
| Stengone Carmine N. | CEO and President | Aug 03 '26 | Sale | $16.01 | 2,500 | $40,029 | 17,217 | Aug 03 06:14 PM |
| Carmine Stengone | Director | Aug 03 '26 | Proposed Sale | $15.49 | 2,500 | $38,725 | — | Aug 03 04:19 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.